Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
Is there any benefit of Anastrozole in addition to Fulvestrant and Palbociclib in a patient with HR+ metastatic breast cancer
Related Questions
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
Would you use elacestrant in a patient with an ESR1-AKAP12 fusion?
Do you use breast MRI or ultrasound to assess tumor size prior to neoadjuvant chemotherapy in breast cancer?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
What are your top takeaways in Breast Cancer from ESMO 2024?
What are your top takeaways in Breast Cancer from ASCO 2024?
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
